Cambridge, UK-based biotech firm Bicycle Therapeutics is to expand its collaboration with AstraZeneca (LSE: AZN), to include additional targets in respiratory and cardio-metabolic diseases.
In 2016 the firms agreed a deal, worth up to $1 billion, to identify and develop bicyclic peptides in these therapy areas, based around Bicycle’s proprietary bicyclic peptide platform.
The firm is developing targeted cytotoxics (bicycle toxin conjugates), targeted innate immune activators and T-cell modulators for cancers of high unmet medical need.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze